Market Performance Snapshot
Over the preceding 24‑hour window ending at 11:44 PM Central European Time on Thursday, 22 October 2026, shares of Innate Pharma (ticker IPH.PA) registered a modest decline of 0.15 %. At the close, the stock traded at approximately EUR 1.30 on the major European exchanges. The company’s current share supply stands at 93.8 million, with a market capitalization of EUR 126.3 million. In the latest trading day, roughly EUR 288.5 thousand of Innate Pharma shares changed hands, reflecting a relatively low liquidity volume compared with its historical averages.
Historically, the stock has shown a pronounced downward swing of 12.35 % since the close of the previous month. The 200‑day simple moving average sits at EUR 1.49, while the 52‑week high—recorded at EUR 2.33 on 13 August 2026—remains a significant outlier above current levels. Conversely, the 52‑week low of EUR 1.03 on 23 March 2026 illustrates the recent range within which the price has oscillated.
Company Outlook and Upcoming Investor Events
Innate Pharma has announced that its senior executive team will participate in two prominent investor conferences scheduled for November 2026. The first event, the Stifel Healthcare Conference in New York, will feature a fireside chat, while the second, the Jefferies Global Healthcare Conference in London, will provide a platform for detailed pipeline discussions. These appearances aim to underscore Innate Pharma’s commitment to advancing next‑generation antibody therapeutics, particularly its lead antibody‑drug conjugate, IPH4502.
The company’s strategy is reinforced through collaborations with key industry partners, including Sobi, Sanofi, and AstraZeneca. Such alliances not only provide access to complementary expertise but also broaden the commercial potential of Innate Pharma’s oncology portfolio. The firm’s dual listing on Euronext Paris and Nasdaq ensures liquidity and visibility across both European and U.S. markets.
Related Market Activity
Within the same 24‑hour period, other biotechnology and healthcare‑sector stocks exhibited varied movements:
| Ticker | 24‑hour % Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|
| LAFA (Lafayette Acquisition) | +0.49 % | USD 10.24 | USD 160.1 million | 69.48 |
| ALHEX.PA (Hexaom) | –4.48 % | EUR 21 | EUR 150.1 million | 7.13 |
| ALLUX.PA (Installux) | 0.00 % | EUR 492 | EUR 137.5 million | 18.25 |
| ALGEV.PA (Gevelot) | +0.53 % | EUR 190 | EUR 142.6 million | 48.76 |
| ALDLT.PA (Delta Plus) | –5.24 % | EUR 19.9 | EUR 149 million | 5.76 |
These figures illustrate a broader market context in which Innate Pharma operates, highlighting the volatility and sectoral dynamics that can influence investor sentiment.
Corporate Profile
Founded in 1999, Innate Pharma is a clinical‑stage biotechnology company headquartered in Marseille, France. Its therapeutic pipeline spans a diverse array of antibody‑based agents designed to address unmet needs in oncology and immunology:
- IPH4102 – targeted for cutaneous T‑cell lymphomas
- Monalizumab – an anti‑NKG2A monoclonal antibody for various malignancies
- IPH5401 – an inhibitor of C5a receptor‑mediated pathways in myeloid‑derived suppressor cells and neutrophils
- Lirilumab – blocks KIR2DL‑1/2/3 inhibitory receptors, enhancing natural killer cell activity
- IPH52 / IPH53 – anti‑CD39 and anti‑CD73 antibodies respectively, focused on tumor immunogenicity
- IPH4301 – an anti‑MICA/B therapeutic antibody
In addition to its research pipeline, Innate Pharma markets a commercial‑stage product, Lumoxiti, for the treatment of hairy cell leukemia. The company’s strategic partnerships include licensing arrangements with AstraZeneca, Bristol‑Myers Squibb, Novo Nordisk, and Sanofi, and a clinical collaboration with MedImmune. It first entered the public markets in 2006, listing on the NYSE via Euronext Paris.
The information presented herein is based on publicly available market data and company disclosures as of the stated dates. Investors should perform independent due diligence before making any investment decisions.
